Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > MedTech analysis

MedTech analysis


  • Sort by Custom
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products ascending
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Biomedtracker / Meddevicetracker Q3 2020 Outlook Report

    $4,750.00

    In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

    July 1, 2020
    Find out more
  • Q3 2022 Outlook Report

    Biomedtracker / Meddevicetracker Q3 2022 Outlook Report

    $4,750.00

    In this report, we cover catalysts from 26 drugs, devices, diagnostics, and deals expected to occur in the third quarter of 2022. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

    July 1, 2022
    Find out more

  • Biomedtracker Early 2021 Outlook Report

    $4,750.00

    In this report, we cover catalysts from 28 drugs, devices, diagnostics, and deals expected to occur in early 2021. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

    February 1, 2021
    Find out more

  • Biomedtracker Q4 2017 Outlook Report

    $4,750.00

    In this report, we cover catalysts from 21 drugs expected to occur in Q4 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

    October 2, 2017
    Find out more

  • Biomedtracker Q4 2020 Outlook Report

    $4,750.00

    In this report, we cover catalysts from 35 drugs, devices, diagnostics, and deals expected to occur in Q4 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

    October 9, 2020
    Find out more

  • Blood Gas Monitoring Systems

    $4,750.00

    Arterial blood gases are the most commonly ordered test in critical care settings such as ICUs and ORs.Tests with rapid turnaround times, such as POC tests, are largely replacing the slower laboratory test market.

    March 28, 2019
    Find out more

  • Bone Densitometers and Bone Turnover Marker Tests

    $4,750.00

    This Meddevicetracker analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the market for bone densitometers (including DXA, QUS, QCT, RA, and SXA systems) and bone turnover marker tests for the US, the five major EU markets, Japan, and the rest of world markets.

    February 15, 2019
    Find out more
  • Bone Grafts and Substitutes Market

    Bone Grafts and Substitutes

    $4,750.00

    This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global market for bone grafts and substitutes. Product segments covered by this report include allografts and synthetic bone substitutes, growth factors, and cellular bone matrices.

    February 15, 2022
    Find out more

  • Brexit and the life sciences: What lies ahead?

    $700.00

    The UK’s surprise decision to leave the EU has caused a great deal of uncertainty about the country’s future, not least among those working in the UK biopharmaceutical and broader life sciences industry.

    August 23, 2016
    Find out more

  • Cardiac Ablation Catheters Market

    $4,750.00

    Cardiac rhythm disorders (also referred to as arrhythmias or dysrhythmias) involve malfunctions of the heart’s electrical system, and may be congenital (present at birth) or acquired (developing after birth).

    May 6, 2021
    Find out more

  • Cochlear Implants Market

    $4,750.00

    This report includes: an overview of hearing loss, cochlear implant technology, competition, trends, and market analysis. Market analysis includes 5-year market forecast by region, market drivers/limiters, global market share and market share by region.

    February 28, 2019
    Find out more

  • Current and Emerging U.S. Markets for Myocardial Revascularization, Repair, and Regeneration Products and Therapies

    $4,750.00

    Approximately 16.3 million adults in the United States (U.S.) suffer from coronaryheart disease (CHD), a type of cardiovascular disease that is associated with areduction in blood flow through the vasculature of the heart (ischemic heart disease).

    March 1, 2013
    Find out more

  • Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

    $4,750.00

    Valued at approximately $1.1bn in 2017, the implantable Deep Brain Stimulation (DBS) and Vagus Nerve Stimulation (VNS) Device Markets are two important and growing neuromodulation segments (outside of the largest, most dynamic $2.5bn segment, Spinal Cord Stimulation or SCS).

    August 31, 2018
    Find out more

  • Diabetes Management: Blood Glucose Monitoring Devices Market

    $4,750.00

    According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.

    December 19, 2019
    Find out more

  • Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

    $4,750.00

    This report provides a detailed presentation of diabetes and blood glucose monitoring devices, including standard fingerstick-based blood glucose meters (BGMs) and new sensor-based continuous glucose monitoring systems (CGMs) that attach to the body and monitor blood glucose 24 hours a day

    March 31, 2021
    Find out more
Page 2 of 13
Page 2 of 13‹1234›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top